Press Release (ePRNews.com) - TORONTO - Aug 23, 2018 - Despite significant advances in the treatment of lung cancer, this disease continues to be the leading cause of cancer death among men and the second-leading cause among women, worldwide. In the European Union alone, approximately 191,900 men and 87,500 women were expected to die of lung cancer in 2015 (age-standardized mortality rate 35.98 and 14.24 per 100,000 in men and women, respectively). In the absence of curative therapies, the objectives of lung cancer treatment are prolongation of survival and the achievement and maintenance of a good quality of life for as long as possible. While this has led to numerous treatments coming to market over the years, including surgery, radiotherapy, chemotherapy, immunotherapy or any combination thereof, it leaves an opportunity to develop new treatments that build on past findings and continuously improve the range of potential outcomes for patients.
Unfortunately, many scientists struggle when it comes to compiling research conducted on previous targets, leading them to continue down pathways that have already been proven to be ineffective. This is why being able to efficiently identify and prioritize novel targets for all diseases, and especially lung cancer, has become an increasingly important step in the drug development process.
In this live webinar, Leo Lafferty-Whyte, Ph.D., Proposition Manager at Clarivate Analytics, and Sonya Novikova, Solution Scientist, Life Sciences at Clarivate Analytics, will demonstrate new ways in which publicly available non-small-cell lung cancer (NSCLC) datasets can be examined in order to find novel approaches to targeting the disease. Specifically, they will discuss how quick and easy it can be (with the right tools) to examine the novelty of the target and the importance of doing so. In the end, the speakers will use these tools to find evidence for core known tumor suppressive mechanisms to be potential targets for NSCLC.
Join the presentation on Tuesday, Sept. 18, 2018, at 11 a.m. EST (4 p.m. BST/UK) to learn:
- The latest trends in lung cancer research
- New techniques for identifying targets, specifically using gene expression analysis
- How to prioritize targets for cancer research more efficiently
For more information about this complimentary event, visit: Identifying Novel Targets for Non-Small Cell Lung Cancer – Just How Novel Are They?
ABOUT CLARIVATE ANALYTICS
Clarivate Analytics is the global leader in providing trusted insights and analytics to accelerate the pace of innovation. Building on a heritage going back more than a century and a half, we have built some of the most trusted brands across the innovation lifecycle, including Web of Science, Cortellis, Derwent, CompuMark, MarkMonitor and Techstreet. Today, Clarivate Analytics is a new and independent company on a bold entrepreneurial mission to help our clients radically reduce the time from new ideas to life-changing innovations.
For more information, please visit https://clarivate.com / https://www.facebook.com/clarivate/ T: @clarivate
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks, visit http://xtalks.com.
For information about hosting a webinar, visit http://xtalks.com/why-host-a-webinar/.
Contact: Source :
Tel: +1 (416) 977-6555 ext 352